Noul Co

Noul Co Gross Margin

The Gross Margin of Noul Co (376930.KQ) as of Oct 30, 2026 is 8.18 %. In the previous year, Gross Margin was 69.29 % — a change of -88.19% (lower).

Gross Margin

8.18 %

YoY

-88.19%

Last updated:

Gross Margin of Noul Co is 2025 8.18 % . Gross Margin of Noul Co was 2024 69.29 % . It decreases by -88.19% lower compared to the previous year.

Noul Co's gross margin stands at 8.2%, down from 25.8% several years earlier.

The Noul Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2020
29.75 KRW
Jan 1, 2021
25.82 KRW
Jan 1, 2022
1.01 KRW
Jan 1, 2023
71.53 KRW
Jan 1, 2024
69.29 KRW
Jan 1, 2025
8.18 KRW
The Noul Co Gross Margin history
YEARGross MarginYoY
8.18 %-88.19%
69.29 %-3.14%
71.53 %+6,992.02%
1.01 %-96.09%
25.82 %-13.22%
29.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Noul Co Stock analysis

What does Noul Co do? Noul Co., Ltd. generates revenue through the manufacture and sale of blood test diagnostic devices utilizing AI algorithms and diagnostic kits. The company offers regular monthly subscriptions via its integrated web-based remote diagnosis system, targeting healthcare providers and medical facilities seeking advanced diagnostic solutions. Its core products include AI-based diagnostic devices and associated kits, sold directly to clinics and hospitals for use in blood testing procedures. The firm's services are designed to enhance diagnostic accuracy and efficiency through remote access and subscription models. The company's primary revenue streams stem from the sale of physical diagnostic devices and diagnostic kits, alongside recurring subscription fees for its web-based remote diagnosis platform. Healthcare institutions and medical professionals form the key customer segments, purchasing both the hardware and ongoing service access. Noul Co., Ltd. focuses on delivering AI-driven diagnostic tools that integrate seamlessly into existing healthcare workflows, emphasizing convenience and technological innovation for its clients. Noul Co., Ltd. operates exclusively within the healthcare diagnostics sector, providing AI-powered blood test solutions that combine hardware sales with subscription-based software services. The business model relies on initial device purchases followed by continuous revenue from monthly subscriptions, creating a sustainable income stream. This approach ensures long-term engagement with healthcare providers while maintaining a focus on cutting-edge diagnostic technology. Noul Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Noul Co stock

Gross Margin of Noul Co is 8.18 % in 2025.

Gross Margin of Noul Co changed from 69.29 % to 8.18 %, representing a -88.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Noul Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Noul Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Noul Co

All Key Metrics — Noul Co